- Cochrane reviewed 77 studies (6,603 participants) and found daily moisturizers cut flare risk to a third of control (RR 0.33) — the single strongest eczema-prevention intervention, though 46 of the included studies had pharmaceutical-company funding.
- Cochrane found no reliable evidence that any one moisturizer ingredient beats another — the "best" moisturizer is the fragrance-free one a person will actually use daily.
- AAD's pediatric guideline recommends against probiotic or vitamin D supplementation specifically for eczema prevention, despite their popularity, because the prevention-specific evidence doesn't clear the bar.
- About 70% of people with atopic dermatitis have a blood relative with atopic dermatitis, asthma, or hay fever, underscoring that genetics plus barrier weakness — not one trigger — usually drives flares (AAD causes page).
- Broad food-elimination diets rarely stop atopic dermatitis and can cause poor growth, nutrient deficiency, and protein malnutrition in children — AAD recommends food testing only when moderate-to-severe eczema stays uncontrolled despite good skin care.
Skin barrier health · Eczema · Evidence-based guide
Eczema is managed best as a skin-barrier disease with flares, not as a one-time rash to “cure.” The strongest evidence supports daily fragrance-free moisturization, trigger reduction, short-course topical anti-inflammatory treatment during flares, and clinician-guided wet wrap therapy for selected moderate-to-severe flares; supplement evidence is weaker, with vitamin D and omega-3 showing possible small benefits in some studies and probiotics or evening primrose oil not supported as routine eczema treatment (AAD guideline, Cochrane emollients review, Cochrane probiotics review, Cochrane evening primrose/borage review).
Table of contents
- Evidence summary
- What eczema is
- All forms and types of eczema
- How eczema works: the flare loop
- Triggers: irritants, allergens, stress, climate, sweat, and infection
- Prevention: what reduces flares
- Management: what to do during a flare
- Supplements for eczema
- What works and what does not
- Risks and all side effects
- All interactions
- Who should avoid or seek medical care first
- FAQ
- Sources
Evidence summary
| Claim | Evidence | Source country / scope | Funding / conflict trace | Strength |
|---|---|---|---|---|
| Daily moisturizers reduce eczema flares and support treatment. | Cochrane reviewed 77 studies with 6,603 participants; moisturizers reduced flares versus control (RR 0.33) and reduced topical corticosteroid use in some trials. | International trials; Cochrane review. | 46 included moisturizer studies had pharmaceutical-company funding; review evidence is useful but downgraded for study sponsorship and bias in many trials. | WORKS Cochrane |
| No one moisturizer ingredient is clearly best for everyone. | Cochrane concluded most moisturizers help but found no reliable evidence that one moisturizer is superior to another. | International trials; Cochrane review. | Same conflict caveat: many included studies were product-funded. | Strong practical verdict Cochrane |
| Topical corticosteroids and topical calcineurin inhibitors are core anti-inflammatory treatments. | AAD gives strong recommendations for topical corticosteroids and topical calcineurin inhibitors in adult and pediatric atopic dermatitis. | United States guideline, globally relevant principles. | AAD page does not state funding or conflicts; guideline-level recommendation, not a product marketing source. | WORKS AAD |
| Bathing and wet wrap therapy can help selected patients but are not one-size-fits-all. | AAD conditionally recommends bathing and wet wrap therapy; a 50-child RCT found both wet wraps and conventional therapy improved SCORAD but did not prove superiority of wet wraps at four weeks. | Guideline plus pediatric RCT. | RCT funding/conflict not prominent in abstracted source; AAD page funding not stated. | MIXED / targeted use AAD / RCT |
| Routine probiotic treatment does not meaningfully improve established eczema for most people. | Cochrane reviewed 39 RCTs with 2,599 participants and found probiotics probably make little or no difference to patient-rated eczema symptoms. | International trials; Cochrane review. | 10 included studies were funded by probiotic suppliers and 4 did not declare funding. | DOESN'T as routine treatment Cochrane |
| Vitamin D may modestly reduce eczema severity in some people, but prevention evidence is not strong enough for routine use. | A 2024 meta-analysis of 11 RCTs and 686 participants found reduced severity (SMD −0.41), while a 2023 meta-analysis of 5 RCTs found no general effect and subgroup uncertainty. | International RCTs and reviews. | 2024 review reported no external funding but disclosed dermatology/pharma relationships for two authors; 2023 review had public Korean funding and no conflicts. | MIXED / targeted 2024 meta-analysis / 2023 meta-analysis |
| Omega-3 evidence is promising but not settled. | A small independent EPA RCT in children reported improved SCORAD over four weeks; Cochrane dietary-supplement review found only possible modest fish-oil benefit from small studies and no convincing evidence for routine supplement use. | Iran pediatric RCT; international Cochrane review. | EPA RCT reported no specific grant and no financial conflicts; Cochrane supplement page did not state funding/conflicts for the review and included small low-quality trials. | MIXED / promising EPA RCT / Cochrane |
| Evening primrose oil and borage oil should not be recommended for eczema treatment. | Cochrane reviewed 27 studies with 1,596 participants and found no statistically significant advantage over placebo. | 12-country evidence base; Cochrane review. | Funding/conflicts not stated on the Cochrane public page; evidence includes older trials but the null result is consistent. | DOESN'T Cochrane |
What eczema is
Eczema is a family of inflammatory skin conditions that cause irritated, dry, itchy, sometimes painful skin; atopic dermatitis is the most common type, but contact dermatitis, stasis dermatitis, dyshidrotic eczema, nummular eczema, hand eczema, seborrheic dermatitis, and neurodermatitis can all sit under the wider eczema/dermatitis umbrella (AAD Eczema Resource Center, AAD atopic dermatitis overview). Atopic dermatitis is not contagious and often begins in childhood, but eczema can begin or persist into adulthood (AAD atopic dermatitis overview, AAD adult eczema).
The practical definition matters: if the rash is mainly a barrier-and-inflammation disease, daily prevention matters even when the skin looks clear; if it is contact dermatitis, identifying the irritant or allergen matters; if it is stasis dermatitis, circulation and leg swelling must be addressed; and if it is seborrheic dermatitis, yeast-associated oily-area inflammation often requires a different plan (AAD contact dermatitis, AAD stasis dermatitis, AAD seborrheic dermatitis treatment).
Text version of this infographic
Eczema is a family of conditions that share inflamed, itchy, barrier-disrupted skin. Main forms include atopic dermatitis, contact dermatitis, hand eczema, dyshidrotic eczema, nummular eczema, stasis dermatitis, seborrheic dermatitis, and neurodermatitis. Identifying the type matters because triggers and treatment priorities differ.
All forms and grades
| Type | Typical pattern | Common drivers or triggers | First management emphasis | Verdict |
|---|---|---|---|---|
| Atopic dermatitis | Chronic, itchy, dry, inflamed skin; often begins early in life but can start at any age. | Barrier weakness, genes, immune activation, dry air, irritants, fragrances, sweat, stress, microbes, and sometimes allergens. | Daily moisturizer, trigger management, anti-inflammatory treatment for flares. | Most common eczema type AAD |
| Contact dermatitis | Rash after something touches skin; can be irritant or allergic. | Soaps, detergents, solvents, plants, metals, fragrances, gloves, topical products. | Find and avoid the irritant/allergen; treat inflammation. | Trigger-identification disease AAD |
| Hand eczema | Dry, thick, scaly hands; cracks, bleeding, burning, blisters, or weeping. | Wet work, water, detergents, solvents, cement, latex, occupational exposure, history of atopic dermatitis. | Glove strategy, barrier repair, avoiding repeated wet/chemical exposure. | High recurrence unless exposures change AAD |
| Dyshidrotic eczema | Tiny intensely itchy blisters on hands or feet; may recur seasonally. | Nickel/cobalt hypersensitivity, personal-care ingredients, medications, smoking, athlete’s foot, stress, sweat, temperature changes. | Identify hypersensitivity, protect hands/feet, manage sweat and irritation. | Blistering hand/foot subtype AAD |
| Nummular eczema | Round or oval itchy plaques, often on hands, forearms, or lower legs. | Very dry skin, skin injury, infection, dry air, heat/humidity, stress, certain medications, contact hypersensitivity. | Repair dryness, treat plaques early, look for contact or infection triggers. | Coin-shaped eczema AAD |
| Stasis dermatitis | Eczema near ankles/lower legs from poor blood flow; also called venous or varicose eczema. | Venous insufficiency, swelling, skin fragility, poor lower-leg circulation. | Manage swelling/circulation plus skin inflammation; rule out ulcers/infection. | Circulation-linked eczema AAD |
| Seborrheic dermatitis | Scaly rash on oily areas such as scalp, face, eyebrows, ears, chest, and skin folds. | Yeast-associated inflammation, oily areas, neurologic/immunologic risk in some people. | Medicated shampoos/antifungals, anti-inflammatory treatment when needed, maintenance care. | Different mechanism than classic dry AD AAD |
| Neurodermatitis | One or two intensely itchy thickened patches from the itch-scratch cycle. | Stress, anxiety, repeated scratching/rubbing, sleep-time itch. | Stop the itch-scratch loop; treat inflammation and behavior trigger. | Itch-scratch-cycle eczema AAD |
How eczema works: the flare loop
Atopic dermatitis often starts with a leaky skin barrier: gaps in the stratum corneum let water escape, allow irritants such as fragrances or dust-mite particles to enter, and make it easier for viruses and bacteria to aggravate inflamed skin (AAD causes page). Genetics, immune overactivity, and what touches the skin interact; AAD notes that about 70% of people with atopic dermatitis have one or more blood relatives with atopic dermatitis or an allergic disease such as asthma or hay fever (AAD causes page).
Original insight: eczema control usually fails when people treat only one part of the loop. A moisturizer repairs water loss but does not fully calm immune inflammation; a steroid calms inflammation but does not replace daily barrier care; trigger avoidance helps but rarely replaces treatment once a flare is active (AAD guideline, AAD food guidance).
Text version of this infographic
- Barrier leak: water escapes and irritants enter.
- Triggers such as soap, sweat, stress, dry air, allergens, or infection worsen the barrier.
- Inflammation causes redness, swelling, and itch.
- Scratching causes micro-injury and increases infection risk.
- The loop is broken by moisturization, trigger avoidance, anti-inflammatory treatment, and sleep/itch control.
Triggers: irritants, allergens, stress, climate, sweat, and infection
Eczema triggers are individual, but AAD lists dry air, sudden temperature change, laundry detergent, baby wipes, stress, heat, sweat, and pool water as common flare drivers in children, while AAD severe-AD guidance also names dry air, sweat, and stress as common aggravators (AAD triggers, AAD severe AD). A systematic review of environmental risk factors found plausible roles for soaps/detergents, sodium lauryl sulfate irritancy, fragrances, nickel/rubber/fragrance exposures, climate, humidity, pollution, tobacco smoke, and stress, with funding from AHRQ and the Dermatology Foundation and no relevant author financial conflicts reported (Environmental risk factors review).
Allergens require precision. AAD states that in most cases atopic dermatitis is not caused or triggered by one specific allergy, even though food allergies, hay fever, or asthma may develop in many people with atopic dermatitis (AAD causes page). Food testing is most appropriate when moderate-to-severe atopic dermatitis remains uncontrolled despite skin care and medicine or when an immediate reaction follows a specific food; broad elimination diets can cause poor growth, nutrient deficiencies, and protein malnutrition in children (AAD food guidance).
| Trigger class | Examples | How to test it safely | What not to do |
|---|---|---|---|
| Irritants | Fragrance, harsh soap, detergents, wipes, solvents, cement, repeated water exposure. | Switch to fragrance-free cleanser/moisturizer for 2–4 weeks and track itch, cracks, and flare frequency. | Do not keep adding botanical oils or “natural” fragranced products; fragrance can still irritate eczema-prone skin. |
| Allergens | Nickel, cobalt, rubber/latex, fragrance allergens, dust mites, animal dander, pollen, mold in selected people. | Use history and clinician-directed patch or allergy testing when patterns fit. | Do not assume a positive IgE or skin test proves the allergen caused every flare. |
| Climate | Dry air, low humidity, heat, sweat, cold-to-warm transitions, seasonal changes. | Track flares against humidity, temperature, exercise, bedding, and bathing. | Do not over-bathe with hot water or leave skin unmoisturized after water exposure. |
| Stress and sleep | Exam stress, work stress, anxiety, bedtime scratching, sleep loss. | Track flare intensity against stressful weeks and nighttime scratching. | Do not frame stress as “all in your head”; stress can worsen itch biology and scratching behavior. |
| Infection | Weeping, crusting, pain, rapidly worsening redness, fever, pustules, herpes-like blisters. | Seek medical care, especially for painful or spreading lesions. | Do not cover a suspected infection with occlusive wet wraps without medical guidance. |
Prevention: what reduces flares
Prevention means reducing flare probability, not guaranteeing no eczema. AAD’s pediatric guideline gives a conditional recommendation for moisturizing skin care to reduce occurrence of atopic dermatitis, but recommends against probiotic or vitamin D supplementation for prevention because the prevention evidence is insufficient or does not show meaningful benefit (AAD guideline, AAD pediatric guideline announcement).
Moisturization protocol
Use a bland, fragrance-free moisturizer as the anchor habit. Cochrane found moisturizers prolong time to flare, reduce flare number, reduce the amount of topical corticosteroid needed in some studies, and work better when combined with active treatment than active treatment alone (Cochrane emollients review). NICE advises unperfumed emollients for children with atopic eczema and says emollients are the basis of management and should continue even when eczema is clear (NICE recommendations).
| Moisturizer form | Best fit | Pros | Cons / side effects | Verdict |
|---|---|---|---|---|
| Ointment / balm | Very dry, cracked, thickened, or winter-flaring skin. | Most occlusive; reduces water loss. | Greasy feel; can trap heat; folliculitis in some people. | Best barrier seal |
| Cream | Daily body use for most people. | Good balance of hydration and acceptability. | Some preservatives or botanicals can sting or irritate. | Best default |
| Lotion | Hair-bearing areas or hot/humid settings when thicker products are intolerable. | Spreads easily. | Less occlusive; may sting due to higher water/preservative content. | Acceptability option |
| Humectant-rich products | Dry but not fissured skin; maintenance. | Glycerin/urea/lactic acid can draw water into stratum corneum. | Urea/lactic acid can sting active eczema; urea had more adverse events in one Cochrane comparison. | Useful but patch-test Cochrane |
| Colloidal oat products | Some itch-prone skin; preference-based use. | Can feel soothing. | Cochrane found no clear superiority for several oat comparisons and possible higher adverse events in one study. | Optional, not magic Cochrane |
Bathing without making eczema worse
Bathing can hydrate skin and remove scale, crust, allergens, irritants, and microbes, but evaporation after bathing can worsen dryness if moisturizer is not applied promptly; AAD conditionally recommends bathing, and AAD public guidance emphasizes baths plus moisturizers as part of eczema control (AAD guideline, AAD food guidance). The safest general approach is lukewarm water, gentle fragrance-free cleanser only where needed, brief bathing if dryness worsens, pat-dry rather than rubbing, and moisturizer while the skin is still slightly damp.
- Daily fragrance-free moisturizer
- Gentle bathing + seal damp skin
- Trigger diary + exposure reduction
- Treat flares early
Text version of this infographic
- The foundation is daily fragrance-free moisturizer.
- The second layer is gentle bathing followed by sealing damp skin with moisturizer.
- The third layer is a trigger diary and targeted exposure reduction.
- The fourth layer is early anti-inflammatory treatment for flares.
- Supplements are optional add-ons and should not replace the core plan.
Management: what to do during a flare
The flare rule is simple: hydrate the barrier and calm inflammation early. AAD strongly recommends moisturizers, topical corticosteroids, topical calcineurin inhibitors, and topical PDE-4/JAK inhibitors for atopic dermatitis where appropriate; AAD conditionally recommends bathing and wet wraps and recommends against routine topical antimicrobials/antiseptics/antihistamines in atopic dermatitis without a specific indication (AAD guideline).
| Management layer | What it does | Best use | Main caution | Evidence verdict |
|---|---|---|---|---|
| Emollients / moisturizers | Reduce water loss and support barrier repair. | Daily prevention and during every flare. | Choose fragrance-free; stop products that sting, burn, or worsen redness. | Core Cochrane |
| Topical corticosteroids | Rapidly reduce inflammatory flare activity. | Short courses matched to body site, age, severity, and clinician plan. | High potency, large-area use, occlusion, thin skin, and long duration increase side-effect risk. | Core flare medicine AAD |
| Topical calcineurin inhibitors | Reduce immune inflammation without steroid skin-thinning. | Sensitive areas, frequent flares, or steroid-sparing maintenance when prescribed. | Burning/stinging is common early; use under clinician direction in immunocompromised people. | Useful steroid-sparing option Review |
| Topical PDE-4 inhibitors | Reduce inflammatory signaling. | Mild-to-moderate eczema when prescribed. | Application-site pain/burning can occur. | Works for selected patients Review |
| Topical JAK inhibitors and newer topical agents | Target cytokine signaling involved in itch/inflammation. | Clinician-selected cases. | Do not stack with systemic immune suppression without medical review. | Medical option AAD |
| Wet wrap therapy | Occludes moisturizer/medicine, cools itch, protects from scratching. | Short-term moderate-to-severe flares under guidance. | Increases topical steroid absorption and may worsen infection risk if done incorrectly. | Targeted rescue layer RCT |
| Phototherapy/systemic medicines | Reduce widespread or severe disease activity. | Moderate-to-severe eczema not controlled with topical care. | Requires specialist management and monitoring. | Specialist layer AAD |
Wet wrap therapy: where it fits
Wet wrap therapy usually means applying moisturizer and sometimes prescribed anti-inflammatory medicine, then covering the area with a damp layer and a dry layer. AAD conditionally recommends wet wraps, while a randomized pediatric study found both wet wraps and conventional care improved SCORAD over four weeks but did not show a significant difference between groups; this makes wet wraps a rescue technique rather than a universal daily routine (AAD guideline, Hindley wet-wrap RCT).
Do not use wet wraps over suspected infection, rapidly spreading rash, painful blisters, or undiagnosed weeping/crusting lesions unless a clinician has assessed the skin. Occlusion increases topical corticosteroid absorption, and NCBI Bookshelf lists occlusive dressings, inflamed skin, large treated areas, high-potency steroids, prolonged use, thin skin, and pediatric body-surface ratio as factors that increase topical corticosteroid exposure (Topical Corticosteroids—NCBI Bookshelf).
- Check red flagspain, fever, pus, herpes-like blisters
- Moisturizebland, fragrance-free, liberal
- Treat inflammationuse prescribed anti-inflammatory
- Protect from scratchnails, sleepwear, wraps if advised
- Find triggersweat, product, stress, weather
Text version of this infographic
Flare action flow: first check for red flags such as pain, fever, pus, spreading redness, or herpes-like blisters; moisturize liberally; use the prescribed anti-inflammatory treatment; reduce scratching with sleepwear, nail care, and clinician-guided wraps when appropriate; identify the likely trigger; escalate care if the flare does not improve or infection is suspected.
Supplements for eczema
Supplements should be considered only after the barrier plan is in place. AAD states that supplement therapies such as probiotic or vitamin D supplementation are not proven for pediatric atopic dermatitis prevention, and AAD food guidance states that when studies are reviewed overall there is little evidence to support specific foods or supplements as eczema fixes (AAD guideline, AAD food guidance).
| Supplement | Evidence for eczema | Possible role | Key safety issues | Verdict |
|---|---|---|---|---|
| Vitamin D | 2024 meta-analysis found modest reduction in severity across 11 RCTs; 2023 meta-analysis found no general effect and high subgroup uncertainty. | Consider only when deficiency risk, low measured status, or clinician-guided correction is relevant. | Excess can cause hypercalcemia, kidney stones, vomiting, weakness, confusion, arrhythmia, renal failure; interacts with thiazides, orlistat, corticosteroids, and some statins. | MIXED / targeted Meta-analysis / NIH ODS |
| Omega-3 EPA/DHA | Small EPA RCT and one product-combination RCT suggest benefit, but Cochrane found no convincing supplement evidence overall. | May be reasonable to discuss for people who also have low seafood intake or other omega-3 indications. | Fishy taste, reflux, nausea, diarrhea, headache; high doses may prolong bleeding time and 4 g/day trials found slightly higher atrial fibrillation risk in high-risk cardiovascular populations. | MIXED / promising EPA RCT / NIH ODS |
| Probiotics | Cochrane found little or no benefit for established eczema; NCCIH notes inconsistent pediatric treatment evidence and preliminary adult strain-specific evidence. | Not a routine eczema treatment; strain selection matters if used. | GI upset; rare serious infection risk in premature infants, severely ill, or immunocompromised people; product contamination/mislabelling concerns. | DOESN'T routinely Cochrane / NCCIH |
| Evening primrose oil / borage oil | Cochrane found no significant benefit across 27 studies. | No evidence-based routine role for eczema. | GI upset, headache, diarrhea; evening primrose oil may increase bleeding risk with warfarin in some reports; long-term safety not established. | DOESN'T Cochrane / NCCIH |
What works and what does not
| Claimed benefit | Verdict | Evidence | Key caveat |
|---|---|---|---|
| “Moisturizer prevents flares.” | WORKS | Cochrane found fewer flares and longer time to flare with moisturizers. | Adherence matters more than trendy ingredients; product sponsorship is common in this literature. Cochrane |
| “A specific moisturizer ingredient is always best.” | DOESN'T | Cochrane found no reliable evidence that one moisturizer is best. | Choose a product the person will use daily without irritation. Cochrane |
| “Topical corticosteroids are unsafe and should be avoided.” | DOESN'T | AAD strongly recommends them; safety risk rises with potency, duration, occlusion, large area, and thin skin. | Fear-driven undertreatment can prolong flares; misuse can cause side effects. AAD / NCBI Bookshelf |
| “Wet wraps are a universal cure.” | MIXED | AAD conditionally recommends; RCT evidence does not prove superiority over well-supported conventional care. | Best as short-term rescue under guidance. AAD / RCT |
| “Food elimination fixes eczema.” | DOESN'T routinely | AAD says removing foods rarely stops AD and broad elimination can harm growth/nutrition in children. | Test only when clinical pattern fits. AAD |
| “Vitamin D works for eczema.” | MIXED | Meta-analyses conflict: modest benefit in 2024, no general effect in 2023. | Likely most rational when correcting deficiency, not as a universal eczema supplement. 2024 review / 2023 review |
| “Probiotics treat eczema.” | DOESN'T routinely | Cochrane found little or no difference in symptoms. | Strain-specific adult evidence is preliminary; high-risk patients need safety review. Cochrane |
| “Evening primrose oil cures eczema.” | DOESN'T | Cochrane found no advantage over placebo. | Can still cause GI effects and bleeding cautions. Cochrane |
Text version of this infographic
The strongest evidence tier is daily moisturizers plus appropriate topical anti-inflammatory medicines. A middle tier includes bathing, wet wraps, vitamin D, and omega-3 for selected cases. Weak routine-treatment evidence applies to probiotics. Negative evidence applies to evening primrose oil and borage oil. Eczema cure claims should be avoided.
Risks and all side effects
| Treatment / ingredient | Common side effects | Uncommon or serious risks | Higher-risk situations | Source |
|---|---|---|---|---|
| Moisturizers | Stinging, burning, itch, redness, folliculitis; urea/lactic acid may sting active eczema. | Allergic contact dermatitis or irritant dermatitis from fragrances, preservatives, botanicals, or lanolin in susceptible people. | Open cracks, infected skin, known contact allergy, products with fragrance/essential oils. | Cochrane |
| Topical corticosteroids | Itching, folliculitis, acneiform eruption, pigment change, skin thinning with misuse. | Atrophy, striae, telangiectasia, delayed wound healing, secondary infection; rare HPA-axis suppression, Cushing syndrome, hyperglycemia, glaucoma with high exposure. | High potency, long duration, large areas, thin skin, occlusion/wet wraps, children, multiple steroid products. | NCBI Bookshelf |
| Topical calcineurin inhibitors | Transient burning, stinging, pain, pruritus at application site. | Theoretical malignancy caution remains in some jurisdictions; reviews have not shown clear increased malignancy risk with typical use. | Weakened immune system, active infection, use without diagnosis, extensive off-label use. | Topical nonsteroid review |
| Topical PDE-4 inhibitors | Application-site pain, burning, stinging. | Serious treatment-related events were not prominent in reviewed crisaborole trials; long-term data are still more limited than older therapies. | Severe burning, open skin, allergy to vehicle ingredients. | Topical nonsteroid review |
| Wet wrap therapy | Chilling, discomfort, maceration, folliculitis, increased stinging. | Higher steroid absorption, adrenal suppression risk in high-exposure contexts, local infection if used over infected lesions. | Infants/young children, high-potency steroids, large body surface area, suspected infection, long duration. | Wet-wrap adrenal study / NCBI Bookshelf |
| Vitamin D | Usually none at appropriate nutritional doses; excess can cause nausea, vomiting, weakness, dehydration, excessive thirst, urination, appetite loss. | Hypercalcemia, hypercalciuria, kidney stones, renal failure, soft-tissue calcification, arrhythmias, death in extreme toxicity. | High-dose supplement stacking, kidney disease, hyperparathyroidism, thiazide diuretics, high calcium intake. | NIH ODS |
| Omega-3 EPA/DHA | Bad breath, unpleasant taste, reflux/heartburn, nausea, GI discomfort, diarrhea, headache, fishy sweat. | High doses can prolong bleeding time; 4 g/day trials in high-risk cardiovascular groups showed slightly higher atrial fibrillation risk. | Anticoagulants/antiplatelets, bleeding disorders, surgery, fish allergy, atrial fibrillation risk. | NIH ODS |
| Probiotics | Gas, bloating, constipation, diarrhea, colic-like GI symptoms. | Rare serious or fatal infections in premature infants or severely ill/immunocompromised people; possible harmful substance production or antibiotic-resistance gene transfer. | Premature infants, central venous catheters, severe illness, immunocompromise, ICU/hospital patients. | NCCIH |
| Evening primrose / borage oil | Headache, abdominal pain, nausea, upset stomach, diarrhea. | Possible bleeding risk with anticoagulants; long-term EPO safety gaps; borage products may vary in pyrrolizidine alkaloid contamination risk depending on quality. | Warfarin or other anticoagulants, surgery, seizure history or complex medication use, pregnancy/lactation without clinician review. | Cochrane / NCCIH |
All interactions
| Treatment / ingredient | Interacts with | Mechanism / concern | Severity | Action |
|---|---|---|---|---|
| Topical corticosteroids | Wet wraps/occlusion; other steroid medicines; thin-skin sites; large-area use. | Occlusion and inflammation increase absorption; total steroid exposure raises systemic-risk probability. | Monitor | Use the lowest effective potency and duration; avoid unsupervised occlusion. NCBI Bookshelf |
| Topical calcineurin inhibitors | Active infection; immunocompromised state; heavy UV exposure/phototherapy unless clinician-directed. | Local immune modulation; theoretical malignancy/infection cautions. | Use caution | Use under diagnosis and clinician plan. Review |
| Wet wraps | Topical corticosteroids; infected skin; large body areas. | Occlusion increases drug absorption and moisture can macerate infected skin. | Avoid unsupervised | Use short-term with clinician guidance. NCBI Bookshelf |
| Vitamin D | Thiazide diuretics. | Reduced urinary calcium excretion plus vitamin D can lead to hypercalcemia, especially with kidney impairment or hyperparathyroidism. | Use caution | Clinician monitoring of calcium and 25(OH)D. NIH ODS |
| Vitamin D | Orlistat and low-fat malabsorption states. | Reduced absorption of fat-soluble vitamin D. | Monitor | Separate and monitor status if medically indicated. NIH ODS |
| Vitamin D | Systemic corticosteroids such as prednisone. | Reduced calcium absorption and impaired vitamin D metabolism. | Monitor | Discuss bone/mineral plan if using repeated or chronic systemic steroids. NIH ODS |
| Vitamin D | Atorvastatin, lovastatin, simvastatin. | High vitamin D intake may reduce potency through shared metabolism. | Monitor | Avoid high-dose self-supplementation. NIH ODS |
| Omega-3 EPA/DHA | Warfarin and similar anticoagulants; antiplatelets. | Antiplatelet effects and possible increased clotting time at high doses. | Monitor | Monitor INR/bleeding risk when dose is high or medications are combined. NIH ODS |
| Omega-3 EPA/DHA | Atrial fibrillation history or high cardiovascular-risk treatment plans. | Large 4 g/day trials found slightly increased atrial fibrillation risk in high-risk groups. | Use caution | Do not start high-dose EPA/DHA without medical oversight. NIH ODS |
| Probiotics | Immunosuppressants, central venous catheters, severe illness, premature infancy. | Rare bloodstream/fungal/bacterial infection risk from live microbes. | Avoid unless supervised | Use only with clinician approval in high-risk groups. NCCIH |
| Evening primrose oil | Warfarin/anticoagulants and surgery. | Possible bleeding effect; Cochrane notes warfarin caution. | Use caution | Avoid around surgery or anticoagulant use unless clinician approves. Cochrane |
Who should avoid or seek medical care first
Seek prompt medical care for eczema with fever, rapidly spreading redness, severe pain, pus, yellow crusting, eye involvement, widespread blistering, or clusters of painful punched-out blisters that could represent eczema herpeticum. AAD notes germs can enter a weakened atopic dermatitis barrier and infection can result, while clinical reviews emphasize treating skin infection as part of eczema care (AAD causes page, Atopic dermatitis review).
People who should not self-manage with supplements or occlusion include infants with severe disease, premature infants, immunocompromised people, people on anticoagulants, people with kidney disease or hypercalcemia risk, people with extensive eczema, and anyone using high-potency topical steroids over large areas. These groups have higher risks from probiotics, vitamin D, omega-3, and topical corticosteroid absorption under occlusion (NCCIH probiotics, NIH ODS vitamin D, NIH ODS omega-3, NCBI Bookshelf topical corticosteroids).
- Is there deficiency?Vitamin D makes more sensewhen correction is needed.
- Is it live?Probiotics need extra cautionin immunocompromised people.
- Bleeding risk?Omega-3 or EPO need cautionwith anticoagulants.
- Is it a cure claim?Eczema cure supplementsfail the evidence test.
- Does it replace care?Never replace moisturizerand flare medicines.
Text version of this infographic
- Ask whether vitamin D deficiency is present before using vitamin D as an eczema supplement.
- Because probiotics are live microbes, use extra caution in premature infants, severely ill people, and immunocompromised people.
- Check bleeding risk before omega-3 or evening primrose oil, especially with anticoagulants or surgery.
- Avoid “eczema cure” supplement claims.
- Supplements should not replace moisturizers, trigger management, or prescribed flare medicines.
Independent evidence, funding, and conflict review
| Source | Independence rating | Credibility rank | Money trail / conflict note | Why it may still be reliable |
|---|---|---|---|---|
| Cochrane emollients review | Probably independent review; underlying evidence partly conflicted. | Strong, with trial-funding caveat. | 46 of 77 included studies had pharmaceutical-company funding. | Transparent methods and explicit risk-of-bias reporting reduce, but do not remove, product-funding distortion risk. |
| AAD atopic dermatitis guideline | Probably independent guideline; funding/conflicts not visible on summary page. | Strong for clinical recommendations. | Public page did not state funding/conflicts. | Guideline recommendations are evidence-graded and publicly accountable to dermatology peers. |
| 2024 vitamin D meta-analysis | Partly conflicted. | Moderate. | No external funding, but two authors disclosed multiple pharma speaker/advisory/research relationships. | Effect estimate is transparent; conflicts argue for conservative interpretation rather than dismissal. |
| EPA pediatric RCT | Independent based on disclosures. | Moderate. | No specific grant; authors declared no financial interest/conflicts. | Randomized blinded design supports signal, but sample size and duration were small. |
| Cochrane probiotics review | Probably independent review; underlying evidence partly conflicted. | Strong for “not routine treatment.” | 10 included studies funded by probiotic suppliers; 4 did not declare funding. | A null or minimal effect despite supplier-funded trials is less likely to be caused by anti-probiotic bias. |
| NCCIH probiotic safety page | Probably independent government/public-health source. | Strong for safety cautions. | NCCIH funds microbiome research but states product mentions are not endorsements. | Public-health mandate and safety-focused framing align incentives toward caution. |
Frequently Asked Questions
What is the fastest evidence-based way to calm an eczema flare?
The fastest practical approach is to moisturize liberally, remove obvious irritants, and use the prescribed topical anti-inflammatory early rather than waiting until the flare is severe. AAD strongly recommends moisturizers and topical anti-inflammatory medicines, while wet wraps are a conditional short-term option for selected flares (AAD guideline).
Should eczema skin be bathed every day?
Bathing can help hydrate skin and remove irritants, but the benefit depends on using lukewarm water, gentle cleanser, and moisturizer immediately afterward. AAD conditionally recommends bathing, and the key is to seal damp skin rather than letting water evaporate and worsen dryness (AAD guideline).
Are topical steroids dangerous for eczema?
Topical corticosteroids are evidence-based flare medicines, but risk rises with high potency, prolonged use, large treated areas, thin skin, and occlusion. Known side effects include skin thinning, striae, telangiectasia, acneiform eruptions, delayed wound healing, and rare systemic effects such as adrenal suppression when exposure is high (NCBI Bookshelf).
Do probiotics help eczema?
For established eczema, not reliably. Cochrane reviewed 39 randomized trials with 2,599 participants and concluded that currently available probiotics probably make little or no difference to patient-rated eczema symptoms (Cochrane probiotics review).
Does vitamin D help eczema?
Vitamin D is mixed: a 2024 meta-analysis found a modest severity reduction across 11 RCTs, while another meta-analysis found no general effect and strong subgroup uncertainty. It is most rational to discuss vitamin D when deficiency correction is relevant, because excess vitamin D can cause hypercalcemia and kidney complications (2024 meta-analysis, NIH ODS vitamin D).
Does fish oil or omega-3 help eczema?
Omega-3 evidence is promising but not settled. A small independent EPA trial in children reported improved SCORAD, but Cochrane found no convincing evidence for dietary supplements as routine eczema treatment and called the fish-oil evidence modest and small-study based (EPA RCT, Cochrane dietary supplements review).
Does evening primrose oil help eczema?
No reliable evidence supports it. Cochrane reviewed 27 studies with 1,596 participants and found no statistically significant advantage for evening primrose oil or borage oil over placebo (Cochrane evening primrose/borage review).
Can food elimination cure eczema?
Food allergy can coexist with eczema, but broad food elimination rarely stops atopic dermatitis and can harm children through poor growth, nutrient deficiency, or protein malnutrition. AAD recommends food allergy testing mainly when moderate-to-severe eczema remains uncontrolled despite good skin care and medication or when an immediate reaction follows a specific food (AAD food guidance).
Sources
- American Academy of Dermatology. Atopic dermatitis clinical guideline. https://www.aad.org/member/clinical-quality/guidelines/atopic-dermatitis
- Cochrane. Emollients and moisturisers for eczema. https://www.cochrane.org/evidence/CD012119_emollients-and-moisturisers-eczema
- Cochrane. Probiotics for treating eczema. https://www.cochrane.org/evidence/CD006135_probiotics-treating-eczema
- Cochrane. Oral evening primrose oil and borage oil for eczema. https://www.cochrane.org/evidence/CD004416_oral-evening-primrose-oil-and-borage-oil-eczema
- Cochrane. Dietary supplements for established atopic eczema in adults and children. https://www.cochrane.org/evidence/CD005205_dietary-supplements-established-atopic-eczema-adults-and-children
- NICE. Atopic eczema in under 12s: diagnosis and management. https://www.nice.org.uk/guidance/cg57/chapter/Recommendations
- AAD. Eczema Resource Center. https://www.aad.org/public/diseases/eczema
- AAD. Atopic dermatitis causes. https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis/causes
- AAD. Childhood eczema triggers. https://www.aad.org/public/diseases/eczema/childhood/triggers
- AAD. Can food fix eczema? https://www.aad.org/public/diseases/eczema/childhood/treating/food-fix
- Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. https://pmc.ncbi.nlm.nih.gov/articles/PMC5216178/
- Hindley D, et al. A randomised study of wet wraps versus conventional treatment for atopic eczema. https://pmc.ncbi.nlm.nih.gov/articles/PMC2082699/
- Nielsen AY, et al. Vitamin D supplementation for treating atopic dermatitis. https://pmc.ncbi.nlm.nih.gov/articles/PMC11644640/
- Park JS, et al. Effect of vitamin D on treatment of atopic dermatitis. https://pmc.ncbi.nlm.nih.gov/articles/PMC10079516/
- Mirrahimi B, et al. Evaluating EPA in children with atopic dermatitis. https://pmc.ncbi.nlm.nih.gov/articles/PMC9901318/
- NIH ODS. Omega-3 fatty acids fact sheet. https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
- NIH ODS. Vitamin D fact sheet. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
- NCCIH. Probiotics: usefulness and safety. https://www.nccih.nih.gov/health/probiotics-usefulness-and-safety
- NCCIH. Evening primrose oil: usefulness and safety. https://www.nccih.nih.gov/health/evening-primrose-oil
- Gabros S, Nessel TA, Zito PM. Topical corticosteroids. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK532940/
- Papier A, Strowd LC. Atopic dermatitis: a review of topical nonsteroid therapy. https://pmc.ncbi.nlm.nih.gov/articles/PMC5886549/